These findings document the involvement of ACSS2 in histone acetylation to control the expression of glutamate receptors in the AD brain and evidence the promising therapeutic potential of ACSS2 targeting and acetate administration in treating patients with intermediate or advanced AD. The gene discussed is ACSS2; the disease is Alzheimer disease.